Linagliptin (BI-1356)

Catalog No.S3031

For research use only.

Linagliptin (BI-1356) is a highly potent, selective DPP-4 inhibitor with IC50 of 1 nM and exhibits a 10,000-fold higher selectivity for DPP-4 than for other dipeptidyl peptidases such as DPP-2, DPP-8, and DPP-9. Linagliptin activates glomerular autophagy in a model of type 2 diabetes. DPP4 mediates ferroptosis in TP53-deficient CRC cells.

Linagliptin (BI-1356) Chemical Structure

CAS No. 668270-12-0

Selleck's Linagliptin (BI-1356) has been cited by 12 Publications

1 Customer Review

Purity & Quality Control

Choose Selective DPP-4 Inhibitors

Other DPP-4 Products

Biological Activity

Description Linagliptin (BI-1356) is a highly potent, selective DPP-4 inhibitor with IC50 of 1 nM and exhibits a 10,000-fold higher selectivity for DPP-4 than for other dipeptidyl peptidases such as DPP-2, DPP-8, and DPP-9. Linagliptin activates glomerular autophagy in a model of type 2 diabetes. DPP4 mediates ferroptosis in TP53-deficient CRC cells.
Targets
Ferroptosis [4]
()
DPP-4 [1]
(cell-free assay)
1 nM
In vitro

Linagliptin shows a potent inhibition effect against DPP-4 in vitro and a low affinity for hERG channel and M1 receptor (IC50 295 nM). [1] Linagliptin acts as a competitive inhibitor with a Ki of 1 nM, and also shows 10,000-fold more selectivity for DPP-4 than DPP-8, DPP-9, amino-peptidases N and P, prolyloligopeptidase, trypsin, plasmin, and thrombin, and 90-fold more selectivity than fibroblast activation protein in vitro. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human Caco-2 cells NXHDd21lTnWwY4Tpc44h[XO|YYm= MoLETY5pcWKrdHnvckBw\iCGUGC0JIlvKGi3bXHuJGNi[29vMjDj[YxteyCjZoTldkAyKGi{LDDJR|UxRTFibl2= MkDvNVg1QDV5MEO=
CHO cells M2LsemZ2dmO2aX;uJIF{e2G7 MXjEbZNxdGGlZX3lcpQhd2ZiW16tcYV1cHmuLUPIYZNkd3CxbHHtbY5mKG[{b32gbJVu[W5icnXjc41jcW6jboSgcZV{[2G{aX7pZ{BOOSC{ZXPldJRweiCneIDy[ZN{\WRiaX6gR2hQKGOnbHzzMEBKSzVyPUCuNlk2KM7:TR?= NITBSHMyQDB3MkCyNy=>
HEK293 cells MmLhSpVv[3Srb36gZZN{[Xl? MmDuTY5pcWKrdHnvckBw\iCvb4Xz[UBz\WOxbXLpcoFvfCCIQWCg[ZhxemW|c3XkJIlvKEiHS{K5N{Bk\WyuczD1d4lv\yCDbHGtVJJwNXBvbnn0do9idmmuaXTlJIF{KHO3YoP0doF1\SCrbnP1ZoF1\WRiZn;yJFE2KG2rboOgdJJqd3JidH:gd5Vje3S{YYTlJIFl\Gm2aX;uMEBKSzVyPUCuN|ch|ryP NVrGOYZEOjR7MEC2PVY>
pig LLC-PK1 cells NIC4SVlHfW6ldHnvckBie3OjeR?= MnjlNVAxKM7:TR?= MnfiUYF5cW2jbDDpcohq[mm2aX;uJI9nKGi3bXHuJHAu\2y7Y3;wdo91\WmwIHX4dJJme3OnZDDpckBxcWdiTFzDMXBMOSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gX|NJZWSrZ3;4bY4he3Wkc4TyZZRmKHS{YX7zdI9zfCCjdDCxNFAhfU1iYomgcIlyfWmmIIPjbY51cWyuYYTpc44h[2:3boTpcoc> NELrboczOzB5M{ezOC=>
Assay
Methods Test Index PMID
Western blot Cyclin D1 / p27 28177527
Growth inhibition assay Cell viability ; Cell viability 28177527 26010513
In vivo

In male Wistar rats, Beagle dogs, and Rhesus monkeys, Linagliptin shows a highly efficacious, long-lasting, and potent inhibitory activity against DPP-4 by more than 70% inhibition for all three species after oral administration of 1 mg/kg. Oral administration of Linagliptin to db/db mice 45 min before an oral glucose tolerance test reduces plasma glucose excursion in a dose-dependent manner from 0.1 mg/kg (15% inhibition) to 1 mg/kg (66% inhibition). [1] By inhibiting DPP-4 activity, Linagliptin reduces the expression of the proinflammatory markers cyclooxygenase-2 and macrophage inflammatory protein-2, and enhances the formation of myofibroblasts in healing wounds from ob/ob mice. [3]

Protocol (from reference)

Animal Research:

[1]

  • Animal Models: Male db/db mice
  • Dosages: ≤1 mg/kg
  • Administration: Administered via p.o.
  • (Only for Reference)

Solubility (25°C)

In vitro

DMSO 17 mg/mL
(35.97 mM)
Water Insoluble
Ethanol '1 mg/mL

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
0.5% hydroxyethyl cellulose
For best results, use promptly after mixing.

30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 472.54
Formula

C25H28N8O2

CAS No. 668270-12-0
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC#CCN1C2=C(N=C1N3CCCC(C3)N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5C(=N4)C)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04180813 Completed Drug: Linagliptin|Drug: Acarbose Diabetes Mellitus Type 2 Boehringer Ingelheim March 4 2020 --
NCT02815644 Completed Drug: empagliflozin/linagliptin FDC Healthy Boehringer Ingelheim July 15 2016 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Linagliptin (BI-1356) | Linagliptin (BI-1356) supplier | purchase Linagliptin (BI-1356) | Linagliptin (BI-1356) cost | Linagliptin (BI-1356) manufacturer | order Linagliptin (BI-1356) | Linagliptin (BI-1356) distributor